Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma

a review of the National Cancer Data Base

Jiayi Huang, Pamela Samson, Stephanie M. Perkins, George Ansstas, Milan G. Chheda, Todd DeWees, Christina I. Tsien, Clifford G. Robinson, Jian L. Campian

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To investigate the utilization and overall survival (OS) impact of concurrent chemotherapy in combination with radiation therapy (RT) for elderly glioblastoma (GBM) patients. Elderly patients (age >70) with supratentorial and nonmetastatic GBM who received RT of 20–75 Gy with concurrent single-agent chemotherapy (ChemoRT) or without (RT alone) during 2004–2012 were identified from the National Cancer Data Base (NCDB). The Cochran-Armitage test was used for trend analysis. Hazard ratios (HR) and 95% confidence intervals (CIs) were determined using Cox proportional hazards. Propensity score analysis was performed to reduce selection bias in treatment allocation. A total of 5252 patients were identified (RT alone: n = 1389; ChemoRT: n = 3863). There was increasing utilization of chemotherapy during this period (45–80%, P <.001). A similar trend was also observed for the subset of age >80 (25–68%, P <.001). ChemoRT was associated with significantly better OS than RT alone (HR 0.79, 95% CI 0.70–0.89, P <.001) on multivariate analysis, and similar OS benefit was demonstrated with 1202 pairs of propensity-matched patients (HR 0.79, 95% CI 0.73–0.86, P <.001). For the matched pair, the median OS was 5.8 months with ChemoRT and 5.0 months with RT alone; the 2-year OS rate was 9% with ChemoRT and 4% with RT alone (P <.001). Concurrent chemotherapy has been administered with RT for the majority of elderly GBM patients. Addition of chemotherapy to RT for elderly GBM patients is associated with significantly improve OS in routine clinical practice.

Original languageEnglish (US)
Pages (from-to)593-601
Number of pages9
JournalJournal of Neuro-Oncology
Volume131
Issue number3
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Glioblastoma
Radiotherapy
Databases
Drug Therapy
Neoplasms
Survival
Confidence Intervals
Propensity Score
Selection Bias
Combination Drug Therapy
Multivariate Analysis
Survival Rate

Keywords

  • Chemotherapy
  • Elderly
  • GBM
  • NCDB
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma : a review of the National Cancer Data Base. / Huang, Jiayi; Samson, Pamela; Perkins, Stephanie M.; Ansstas, George; Chheda, Milan G.; DeWees, Todd; Tsien, Christina I.; Robinson, Clifford G.; Campian, Jian L.

In: Journal of Neuro-Oncology, Vol. 131, No. 3, 01.02.2017, p. 593-601.

Research output: Contribution to journalArticle

Huang, Jiayi ; Samson, Pamela ; Perkins, Stephanie M. ; Ansstas, George ; Chheda, Milan G. ; DeWees, Todd ; Tsien, Christina I. ; Robinson, Clifford G. ; Campian, Jian L. / Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma : a review of the National Cancer Data Base. In: Journal of Neuro-Oncology. 2017 ; Vol. 131, No. 3. pp. 593-601.
@article{396424d3de3641c5b43921a3b14d5867,
title = "Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base",
abstract = "To investigate the utilization and overall survival (OS) impact of concurrent chemotherapy in combination with radiation therapy (RT) for elderly glioblastoma (GBM) patients. Elderly patients (age >70) with supratentorial and nonmetastatic GBM who received RT of 20–75 Gy with concurrent single-agent chemotherapy (ChemoRT) or without (RT alone) during 2004–2012 were identified from the National Cancer Data Base (NCDB). The Cochran-Armitage test was used for trend analysis. Hazard ratios (HR) and 95{\%} confidence intervals (CIs) were determined using Cox proportional hazards. Propensity score analysis was performed to reduce selection bias in treatment allocation. A total of 5252 patients were identified (RT alone: n = 1389; ChemoRT: n = 3863). There was increasing utilization of chemotherapy during this period (45–80{\%}, P <.001). A similar trend was also observed for the subset of age >80 (25–68{\%}, P <.001). ChemoRT was associated with significantly better OS than RT alone (HR 0.79, 95{\%} CI 0.70–0.89, P <.001) on multivariate analysis, and similar OS benefit was demonstrated with 1202 pairs of propensity-matched patients (HR 0.79, 95{\%} CI 0.73–0.86, P <.001). For the matched pair, the median OS was 5.8 months with ChemoRT and 5.0 months with RT alone; the 2-year OS rate was 9{\%} with ChemoRT and 4{\%} with RT alone (P <.001). Concurrent chemotherapy has been administered with RT for the majority of elderly GBM patients. Addition of chemotherapy to RT for elderly GBM patients is associated with significantly improve OS in routine clinical practice.",
keywords = "Chemotherapy, Elderly, GBM, NCDB, Radiation therapy",
author = "Jiayi Huang and Pamela Samson and Perkins, {Stephanie M.} and George Ansstas and Chheda, {Milan G.} and Todd DeWees and Tsien, {Christina I.} and Robinson, {Clifford G.} and Campian, {Jian L.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s11060-016-2331-6",
language = "English (US)",
volume = "131",
pages = "593--601",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma

T2 - a review of the National Cancer Data Base

AU - Huang, Jiayi

AU - Samson, Pamela

AU - Perkins, Stephanie M.

AU - Ansstas, George

AU - Chheda, Milan G.

AU - DeWees, Todd

AU - Tsien, Christina I.

AU - Robinson, Clifford G.

AU - Campian, Jian L.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - To investigate the utilization and overall survival (OS) impact of concurrent chemotherapy in combination with radiation therapy (RT) for elderly glioblastoma (GBM) patients. Elderly patients (age >70) with supratentorial and nonmetastatic GBM who received RT of 20–75 Gy with concurrent single-agent chemotherapy (ChemoRT) or without (RT alone) during 2004–2012 were identified from the National Cancer Data Base (NCDB). The Cochran-Armitage test was used for trend analysis. Hazard ratios (HR) and 95% confidence intervals (CIs) were determined using Cox proportional hazards. Propensity score analysis was performed to reduce selection bias in treatment allocation. A total of 5252 patients were identified (RT alone: n = 1389; ChemoRT: n = 3863). There was increasing utilization of chemotherapy during this period (45–80%, P <.001). A similar trend was also observed for the subset of age >80 (25–68%, P <.001). ChemoRT was associated with significantly better OS than RT alone (HR 0.79, 95% CI 0.70–0.89, P <.001) on multivariate analysis, and similar OS benefit was demonstrated with 1202 pairs of propensity-matched patients (HR 0.79, 95% CI 0.73–0.86, P <.001). For the matched pair, the median OS was 5.8 months with ChemoRT and 5.0 months with RT alone; the 2-year OS rate was 9% with ChemoRT and 4% with RT alone (P <.001). Concurrent chemotherapy has been administered with RT for the majority of elderly GBM patients. Addition of chemotherapy to RT for elderly GBM patients is associated with significantly improve OS in routine clinical practice.

AB - To investigate the utilization and overall survival (OS) impact of concurrent chemotherapy in combination with radiation therapy (RT) for elderly glioblastoma (GBM) patients. Elderly patients (age >70) with supratentorial and nonmetastatic GBM who received RT of 20–75 Gy with concurrent single-agent chemotherapy (ChemoRT) or without (RT alone) during 2004–2012 were identified from the National Cancer Data Base (NCDB). The Cochran-Armitage test was used for trend analysis. Hazard ratios (HR) and 95% confidence intervals (CIs) were determined using Cox proportional hazards. Propensity score analysis was performed to reduce selection bias in treatment allocation. A total of 5252 patients were identified (RT alone: n = 1389; ChemoRT: n = 3863). There was increasing utilization of chemotherapy during this period (45–80%, P <.001). A similar trend was also observed for the subset of age >80 (25–68%, P <.001). ChemoRT was associated with significantly better OS than RT alone (HR 0.79, 95% CI 0.70–0.89, P <.001) on multivariate analysis, and similar OS benefit was demonstrated with 1202 pairs of propensity-matched patients (HR 0.79, 95% CI 0.73–0.86, P <.001). For the matched pair, the median OS was 5.8 months with ChemoRT and 5.0 months with RT alone; the 2-year OS rate was 9% with ChemoRT and 4% with RT alone (P <.001). Concurrent chemotherapy has been administered with RT for the majority of elderly GBM patients. Addition of chemotherapy to RT for elderly GBM patients is associated with significantly improve OS in routine clinical practice.

KW - Chemotherapy

KW - Elderly

KW - GBM

KW - NCDB

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84995376351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995376351&partnerID=8YFLogxK

U2 - 10.1007/s11060-016-2331-6

DO - 10.1007/s11060-016-2331-6

M3 - Article

VL - 131

SP - 593

EP - 601

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -